Clinical trials: Neoplasm Recurrence
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
The purpose of this study is to determine if a new drug, RO4929097, can work with cetuximab, a drug already approved for colorectal cancer, to help fight the patient's cancer.
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01198535
- Testing
- Cetuximab, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Thymic Carcinoma
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients…
- Conditions
- Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
- Trial name
- NCT01025089
- Testing
- Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Biliary Tract Neoplasms, Biliary Drainage
Suprapapillary Versus Transpapillary Plastic Stents for Unresectable Malignant Hilar Biliary Obstruction
Bile duct blockage caused by cancer near the liver hilum (where the bile ducts join) leads to jaundice and infection. The standard treatment is to place a plastic stent (a small tube) through an endoscope to drain the bile.
- Conditions
- Biliary Tract Neoplasms, Biliary Drainage, Malignant Biliary Obstruction, Obstructive Jaundice
- Trial name
- NCT07811791
- Testing
- Suprapapillary plastic stent placement, Transpapillary plastic stent placement
- Where
- 8 sites in Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
HCC, Adjuvant Therapy
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk…
- Conditions
- HCC, Adjuvant Therapy, Immunotherapy
- Trial name
- DaDaLi (NCT04682210)
- Testing
- Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial studies the side effects and how well CART-BCMA/CS1 works in treating patients with multiple myeloma (MM) that has come back (relapsed) or that does not respond to treatment (refractory).
- Trial name
- NCT05950113
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastrointestinal Stromal Tumor (GIST)
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence…
- Trial name
- NCT00867113
- Testing
- imatinib mesylate
- Where
- 21 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Glioma, Glioblastoma
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT02176720
- Testing
- FDOPA PET
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- The Methodist Hospital Research Institute
Glioblastoma
Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma
This multi-center randomized controlled phase II trial will investigate the impact of stereotactic fractionated radiotherapy to the resection cavity of complete resected recurrent glioblastoma on progression free survival.
- Trial name
- GlioCave/NOA17 (NCT02715297)
- Testing
- SRT to the resection cavity
- Where
- Germany
- Volunteers
- 162 people
- Sponsor
- Technical University of Munich
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Cancer
COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF
Cancer Center Psychosocial services (Psycho-Oncology) offers group psychoeducational and behavioral programs as part of its clinical service for cancer patients and services at the Helen Diller Family Comprehensive Cancer Center.
- Trial name
- NCT04636346
- Testing
- Acceptance and Commitment Therapy, Questionnaires
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of California, San Francisco
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Ovarian Tumors
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel. Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a…
- Trial name
- NCT04711161
- Testing
- GRN-300, Paclitaxel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Green3Bio, Inc.
Stage IV Colon Cancer, Recurrent Colon Cancer
Antineoplaston Therapy in Treating Patients With Colon Cancer
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Stage IV Colon Cancer, Recurrent Colon Cancer, Adenocarcinoma of the Colon
- Trial name
- NCT00003486
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Platinum-resistant Ovarian Cancer
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance.
- Trial name
- ANNIE (NCT04376073)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jihong Liu
Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
This phase I trial studies the side effects and best dose of entolimod in treating patients with stage III-IV or recurrent head and neck cancer.
- Conditions
- Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01728480
- Testing
- entolimod, intensity-modulated radiation therapy, cisplatin
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00798603
- Testing
- bevacizumab, carboplatin, pemetrexed disodium
- Where
- 217 sites in United States
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer, Neoplasms, Ovarian
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer.
- Trial name
- NCT00316173
- Testing
- topotecan, CARBOPLATIN
- Where
- 22 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Recurrent Glioblastoma, Recurrent Gliosarcoma
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent).
- Trial name
- NCT05017610
- Testing
- Liothyronine, Lomustine, Methimazole
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.